EDITAS MEDICINE, INC. Stock-Based Compensation
EDITAS MEDICINE, INC. (EDIT) reported Stock-Based Compensation of $4.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- EDITAS MEDICINE, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.19M, a 17.68% decline year-over-year.
- EDITAS MEDICINE, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.10M, a 29.44% decline year-over-year.
- EDITAS MEDICINE, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.13M, a 47.04% decline year-over-year.
- EDITAS MEDICINE, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.23M, a 53.60% decline year-over-year.
- EDITAS MEDICINE, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $10.00M, a 53.31% decline from fiscal 2024.
- EDITAS MEDICINE, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $21.42M, a 8.18% increase from fiscal 2023.
- EDITAS MEDICINE, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $19.80M, a 32.42% decline from fiscal 2022.
- EDITAS MEDICINE, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $29.29M, a 32.50% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.29M 10-Q · filed 2026-08-05 | $6.42M derived: sum of 3 quarters · filed 2026-08-05 | $8.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.10M 10-Q · filed 2026-05-05 | $4.23M derived: sum of 2 quarters · filed 2026-05-05 | $6.46M derived: sum of 3 quarters · filed 2026-05-05 | $9.12M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $4.36M derived: sum of 2 quarters · filed 2026-03-09 | $7.02M derived: sum of 3 quarters · filed 2026-08-05 | $10.00M 10-K · filed 2026-03-09 |
| 2025-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.89M derived: sum of 2 quarters · filed 2026-08-05 | $7.87M 10-Q · filed 2025-11-10 | $11.89M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.64M 10-Q · filed 2026-08-05 | $9.66M derived: sum of 3 quarters · filed 2026-08-05 | $14.46M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.98M 10-Q · filed 2026-05-05 | $7.00M derived: sum of 2 quarters · filed 2026-05-05 | $11.80M derived: sum of 3 quarters · filed 2026-05-05 | $16.81M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $4.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $8.82M derived: sum of 2 quarters · filed 2026-03-09 | $13.83M derived: sum of 3 quarters · filed 2026-03-09 | $21.42M 10-K · filed 2026-03-09 |
| 2024-09-30 | $4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $9.81M derived: sum of 2 quarters · filed 2025-11-10 | $17.40M 10-Q · filed 2025-11-10 | $22.74M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $5.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $12.60M 10-Q · filed 2025-08-12 | $17.94M derived: sum of 3 quarters · filed 2025-08-12 | $22.67M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $7.58M 10-Q · filed 2025-05-12 | $12.93M derived: sum of 2 quarters · filed 2025-05-12 | $17.66M derived: sum of 3 quarters · filed 2025-05-12 | $22.88M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $5.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $10.08M derived: sum of 2 quarters · filed 2025-03-05 | $15.29M derived: sum of 3 quarters · filed 2025-03-05 | $19.80M 10-K · filed 2025-03-05 |
| 2023-09-30 | $4.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $9.95M derived: sum of 2 quarters · filed 2024-11-04 | $14.45M 10-Q · filed 2024-11-04 | $19.82M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | $5.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $9.72M 10-Q · filed 2024-08-07 | $15.09M derived: sum of 3 quarters · filed 2025-03-05 | $20.97M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | $4.51M 10-Q · filed 2024-05-08 | $9.87M derived: sum of 2 quarters · filed 2025-03-05 | $15.75M derived: sum of 3 quarters · filed 2025-03-05 | $22.37M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $5.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $11.24M derived: sum of 2 quarters · filed 2025-03-05 | $17.86M derived: sum of 3 quarters · filed 2025-03-05 | $29.29M 10-K · filed 2025-03-05 |
| 2022-09-30 | $5.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $12.50M derived: sum of 2 quarters · filed 2023-11-03 | $23.93M 10-Q · filed 2023-11-03 | $31.59M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $6.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $18.05M 10-Q · filed 2023-08-02 | $25.71M derived: sum of 3 quarters · filed 2024-02-28 | $35.72M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $11.43M 10-Q · filed 2023-05-05 | $19.09M derived: sum of 2 quarters · filed 2024-02-28 | $29.10M derived: sum of 3 quarters · filed 2024-02-28 | $42.63M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $7.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $17.67M derived: sum of 2 quarters · filed 2024-02-28 | $31.20M derived: sum of 3 quarters · filed 2024-02-28 | $43.40M 10-K · filed 2024-02-28 |
| 2021-09-30 | $10.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $23.54M derived: sum of 2 quarters · filed 2022-11-02 | $35.74M 10-Q · filed 2022-11-02 | $41.41M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $13.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $25.73M 10-Q · filed 2022-08-03 | $31.40M derived: sum of 3 quarters · filed 2023-02-22 | $37.25M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $12.20M 10-Q · filed 2022-05-04 | $17.88M derived: sum of 2 quarters · filed 2023-02-22 | $23.72M derived: sum of 3 quarters · filed 2023-02-22 | $29.14M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $11.52M derived: sum of 2 quarters · filed 2023-02-22 | $16.94M derived: sum of 3 quarters · filed 2023-02-22 | $23.16M 10-K · filed 2023-02-22 |
| 2020-09-30 | $5.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $11.26M derived: sum of 2 quarters · filed 2021-11-09 | $17.48M 10-Q · filed 2021-11-09 | $23.82M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $5.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $11.64M 10-Q · filed 2021-08-05 | $17.97M derived: sum of 3 quarters · filed 2022-02-24 | $24.53M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $6.22M 10-Q · filed 2021-05-06 | $12.56M derived: sum of 2 quarters · filed 2022-02-24 | $19.11M derived: sum of 3 quarters · filed 2022-02-24 | $25.61M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $6.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $12.89M derived: sum of 2 quarters · filed 2022-02-24 | $19.39M derived: sum of 3 quarters · filed 2022-02-24 | $27.24M 10-K · filed 2022-02-24 |
| 2019-09-30 | $6.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $13.05M derived: sum of 2 quarters · filed 2020-11-06 | $20.91M 10-Q · filed 2020-11-06 | $27.25M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $6.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $14.35M 10-Q · filed 2020-08-07 | $20.70M derived: sum of 3 quarters · filed 2021-02-26 | $27.39M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $7.86M 10-Q · filed 2020-05-08 | $14.20M derived: sum of 2 quarters · filed 2021-02-26 | $20.90M derived: sum of 3 quarters · filed 2021-02-26 | $27.93M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $6.35M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $13.05M derived: sum of 2 quarters · filed 2021-02-26 | $20.07M derived: sum of 3 quarters · filed 2021-02-26 | $26.60M 10-K · filed 2021-02-26 |
| 2018-09-30 | $6.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $13.72M derived: sum of 2 quarters · filed 2019-11-12 | $20.25M 10-Q · filed 2019-11-12 | $28.33M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $7.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $13.55M 10-Q · filed 2019-08-07 | $21.63M derived: sum of 3 quarters · filed 2020-02-26 | $26.10M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $6.53M 10-Q · filed 2019-05-08 | $14.61M derived: sum of 2 quarters · filed 2020-02-26 | $19.07M derived: sum of 3 quarters · filed 2020-02-26 | $24.09M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $8.08M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $12.54M derived: sum of 2 quarters · filed 2020-02-26 | $17.56M derived: sum of 3 quarters · filed 2020-02-26 | $23.36M 10-K · filed 2020-02-26 |
| 2017-09-30 | $4.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $9.48M derived: sum of 2 quarters · filed 2018-11-08 | $15.29M 10-Q · filed 2018-11-08 | $19.07M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $5.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $10.82M 10-Q · filed 2018-08-07 | $14.60M derived: sum of 3 quarters · filed 2019-03-01 | $18.29M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $5.80M 10-Q · filed 2018-05-04 | $9.59M derived: sum of 2 quarters · filed 2019-03-01 | $13.28M derived: sum of 3 quarters · filed 2019-03-01 | $18.48M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $3.78M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $7.47M derived: sum of 2 quarters · filed 2019-03-01 | $12.67M derived: sum of 3 quarters · filed 2019-03-01 | $16.88M 10-K · filed 2019-03-01 |
| 2016-09-30 | $3.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $8.89M derived: sum of 2 quarters · filed 2017-11-08 | $13.10M 10-Q · filed 2017-11-08 | $15.05M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $5.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $9.41M 10-Q · filed 2017-08-09 | $11.36M derived: sum of 3 quarters · filed 2018-03-08 | $12.42M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $4.21M 10-Q · filed 2017-05-15 | $6.16M derived: sum of 2 quarters · filed 2018-03-08 | $7.22M derived: sum of 3 quarters · filed 2018-03-08 | $7.66M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $3.01M derived: sum of 2 quarters · filed 2018-03-08 | $3.45M derived: sum of 3 quarters · filed 2018-03-08 | $3.51M 10-K · filed 2018-03-08 |
| 2015-09-30 | $1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $1.50M derived: sum of 2 quarters · filed 2016-11-09 | $1.56M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $440.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $505.00K 10-Q · filed 2016-08-10 | ||
| 2015-03-31 | $65.00K 10-Q · filed 2016-05-13 | |||
| 2014-12-31 | $55.00K 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |